While various HDAC inhibitors have been studied and developed for cancer therapy due to their anti-proliferative effects, increasing evidence shows that SAHA, at lower and non-cytotoxic concentrations, exhibits potent anti-inflammatory and immunomodulatory activities in vitro[3-6] and in vivo[4,7]. Here, HDAC9 is linked to cancer.